Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Status:
Completed
Trial end date:
2020-07-09
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in
patients with stage I/II Hodgkin's lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity
after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).